Tislelizumab for treating unresectable, previously untreated hepatocellular carcinoma


featured image

Tislelizumab is being developed for the first-line treatment of unresectable hepatocellular carcinoma (HCC). HCC is the most common type of liver cancer and the leading cause of cancer related death worldwide.

Therapeutic Areas: Gastrointestinal Cancer
Year: 2022

Tislelizumab is being developed for the first-line treatment of unresectable hepatocellular carcinoma (HCC). HCC is the most common type of liver cancer and the leading cause of cancer related death worldwide. This type of cancer develops from the main liver cells, called hepatocytes. Liver cancer is more common in people who have long‐term damage to the liver (cirrhosis) due to hepatitis infection or excessive alcohol intake and metabolic causes such as obesity. HCC is also more likely to develop in men than in women and it becomes more common as people get older. Patients with unresectable HCC, where the tumour cannot be removed through surgery, have a poor prognosis and there are currently few first-line treatment options available.